HTD Biosystems
HTD Biosystems is a private biotech company based in Livermore, California, specializing in drug development, formulation, and characterization services for biopharmaceuticals, vaccines, liposomal systems, and nanoparticles. They focus on accelerating drug development from discovery to the clinic through innovative solutions, flexible collaboration, and advanced analytical techniques.
Industries
Nr. of Employees
small (1-50)
HTD Biosystems
Products
High-throughput formulation optimization platform
Algorithm-driven platform for rapid formulation screening that uses design of experiments and modeling approaches (including machine learning/AI) to identify stable, pharmaceutically acceptable formulations.
High-throughput formulation optimization platform
Algorithm-driven platform for rapid formulation screening that uses design of experiments and modeling approaches (including machine learning/AI) to identify stable, pharmaceutically acceptable formulations.
Services
Contract formulation development for biologics (monoclonal and bispecific antibodies, ADCs, enzymes, peptides, nucleic acids) across liquid, frozen and lyophilized presentations; excipient selection, co-formulation and high-concentration strategies.
Development and optimization of lyophilization cycles, analytical assessment of lyophilized cake properties, residual moisture testing, and pilot-scale lyophilization with transfer to manufacturing.
Bioanalytical services to determine identity, purity, content, stability and activity of protein products using orthogonal and high-throughput methods (DSF, DLS, HPLC, UV spectroscopy, FlowCam, SEC).
Design and development of liposomal vaccines and lipid nanoparticle formulations, including control of size, payload encapsulation and properties for targeted delivery.
Formulation and small-batch production of vaccine candidates across multiple platforms, with in vitro and in vivo immunogenicity and safety testing support (e.g., ELISA, animal models).
GLP-compliant manufacturing of parenteral products for preclinical studies including aseptic fill–finish, sterilization and packaging workflows to support toxicology programs.
Contract formulation development for biologics (monoclonal and bispecific antibodies, ADCs, enzymes, peptides, nucleic acids) across liquid, frozen and lyophilized presentations; excipient selection, co-formulation and high-concentration strategies.
Development and optimization of lyophilization cycles, analytical assessment of lyophilized cake properties, residual moisture testing, and pilot-scale lyophilization with transfer to manufacturing.
Bioanalytical services to determine identity, purity, content, stability and activity of protein products using orthogonal and high-throughput methods (DSF, DLS, HPLC, UV spectroscopy, FlowCam, SEC).
Design and development of liposomal vaccines and lipid nanoparticle formulations, including control of size, payload encapsulation and properties for targeted delivery.
Formulation and small-batch production of vaccine candidates across multiple platforms, with in vitro and in vivo immunogenicity and safety testing support (e.g., ELISA, animal models).
GLP-compliant manufacturing of parenteral products for preclinical studies including aseptic fill–finish, sterilization and packaging workflows to support toxicology programs.
Expertise Areas
- Protein formulation development
- Lyophilization and freeze-drying cycle optimization
- Liposomal and lipid nanoparticle (LNP) formulation
- Vaccine formulation and preclinical testing
Key Technologies
- Differential scanning calorimetry (DSC)
- Differential scanning fluorimetry (DSF / nDSF)
- Dynamic light scattering (DLS)
- Flow imaging microscopy (FlowCam)
News & Updates
HTD Biosystems uses FlowCam Imaging to measure sub-visible particles in parenteral products, supporting formulation development, developability screening, and GLP lot release.
Dr. Mitra Mosharraf, Chief Scientific Officer, featured in 'Ask the Experts' on nanoparticle characterization, sharing over 24 years of experience, and supporting nanoparticle, liposome, and ADC development.
HTD representatives presented posters and talks on LNPs, COVID-19 vaccines, and liposomal formulations at major industry conferences, highlighting their expertise in nanomedicine.
HTD Biosystems uses FlowCam Imaging to measure sub-visible particles in parenteral products, supporting formulation development, developability screening, and GLP lot release.
Dr. Mitra Mosharraf, Chief Scientific Officer, featured in 'Ask the Experts' on nanoparticle characterization, sharing over 24 years of experience, and supporting nanoparticle, liposome, and ADC development.
HTD representatives presented posters and talks on LNPs, COVID-19 vaccines, and liposomal formulations at major industry conferences, highlighting their expertise in nanomedicine.